Research Lab Review

Mazdutide vs dulaglutide: what a meta-analysis of 3 trials shows

News · Mazdutide

A meta-analysis of three randomized trials links mazdutide to larger HbA1c and weight drops than dulaglutide, with more gastrointestinal side effects.

A new meta-analysis has pooled the randomized trials that compared mazdutide, a dual GLP-1 and glucagon receptor agonist, with the GLP-1 receptor agonist dulaglutide in adults with type 2 diabetes [1]. Mazdutide was linked to larger drops in HbA1c and body weight, but also to more gastrointestinal side effects [1]. The analysis rests on only three trials, so it is an early signal about whether adding glucagon signaling changes outcomes in type 2 diabetes, not a final answer [1].

Key takeaways

  • A systematic review and meta-analysis of three randomized controlled trials found greater average reductions in HbA1c (-0.25 percentage points) and body weight (-2.97 kg) with mazdutide than with dulaglutide [1].
  • Gastrointestinal side effects and decreased appetite were more common with mazdutide. Serious adverse events and discontinuations were similar between the two [1].
  • The authors call the findings preliminary because of the small number of trials, and they call for larger, longer-term studies [1].
  • A narrative review notes that whether glucagon/GLP-1 dual agonists outperform GLP-1-only drugs “remains to be established in definitive head-to-head studies” [2].

Microscope cross section of adipose tissue showing fat cells at 200x magnification

The meta-analysis: what was compared

The first source is a systematic review and meta-analysis of randomized controlled trials that compared mazdutide directly with dulaglutide in adults with type 2 diabetes [1]. The researchers searched for eligible trials, pooled the data using random-effects models, and rated the certainty of the evidence with the GRADE approach [1]. Three trials met their inclusion criteria [1]. The abstract does not report the total number of participants, so the overall sample size is not stated here.

The main outcomes were changes in HbA1c (a measure of average blood sugar over the previous few months) and body weight. The authors also looked at how many people reached set targets: HbA1c below 7.0%, at least 5% weight loss, and both at once [1]. The safety outcomes were treatment-emergent adverse events [1].

What the pooled results showed

Across the three trials, mazdutide was associated with an average HbA1c reduction 0.25 percentage points greater than dulaglutide, and an average weight reduction 2.97 kg greater [1]. Participants given mazdutide were more likely to reach HbA1c below 7.0%, to lose at least 5% of their body weight, and to meet both targets together [1].

Not every measure moved clearly. Fasting plasma glucose was numerically better with mazdutide, but the difference was not statistically significant [1].

The authors rated the glycemic outcomes and the major weight outcomes as high-certainty evidence under GRADE [1]. That rating describes confidence in the pooled estimates from the trials that were included. It does not settle questions those trials were not designed to answer, such as long-term outcomes.

The safety picture

The trade-off showed up mainly in the gut. Mazdutide was associated with higher rates of gastrointestinal side effects and decreased appetite than dulaglutide [1]. Hypoglycemia (low blood sugar) was numerically more common with mazdutide, but the difference was not statistically significant [1]. Rates of serious adverse events and of stopping treatment were similar between the two drugs [1].

The authors describe the gastrointestinal effects as “mostly manageable” [1]. Most of the safety outcomes were rated moderate-certainty evidence, a step below the efficacy outcomes [1]. Three trials also give limited ability to detect uncommon side effects.

Limits of this analysis

  • Few trials. Only three randomized trials were pooled, and the authors themselves call the conclusions preliminary [1].
  • One comparator. Mazdutide was compared only with dulaglutide [1]. The results do not show how it compares with other GLP-1 receptor agonists or with other multi-target drugs.
  • Length and size. The authors say larger, longer-term trials are needed to confirm the findings [1]. The abstract does not give trial durations or participant numbers.
  • Population. The included trials enrolled adults with type 2 diabetes [1]. The results may not apply to other groups, such as people with obesity but without diabetes, or to younger people.

Why add glucagon? The translational case

The second source is a narrative review with a translational focus [2]. It explains why researchers are paying fresh attention to glucagon, a pancreatic hormone best known for raising blood sugar [2]. The review describes evidence that glucagon plays a wider role in metabolism, including energy balance and liver health [2].

The obvious concern is that glucagon signaling can raise blood sugar. According to the review, this is why most compounds under study are dual agonists that act on both the glucagon and GLP-1 receptors [2]. The idea is that GLP-1 signaling, with its glucose-lowering and appetite-reducing effects, offsets that risk [2].

The evidence the review summarizes comes in layers:

  • Animal studies. In animal models of obesity and metabolic dysfunction-associated steatohepatitis (MASH), glucagon/GLP-1 dual agonists reduced food intake, lowered liver fat and increased energy expenditure [2]. These are animal results and cannot be assumed to apply to people.
  • Early human trials. Some dual agonists substantially reduced body weight, liver fat and liver fibrosis in early clinical trials [2].
  • Balance between the two signals. The review notes that the ratio of glucagon to GLP-1 activity in each compound appears to matter, and that glycemic control worsened with some dual agonists [2].

The review states that mazdutide has been approved for chronic weight management and type 2 diabetes in China, and that survodutide, another dual agonist, is in global phase 3 trials [2]. It reports that both had strong weight-loss and glucose-lowering effects in people with obesity, and that survodutide also improved liver health in people with MASH [2].

The review is a narrative review, not a systematic one, so its authors chose which studies to discuss. It is also clear that superiority over GLP-1-only drugs has not yet been shown in definitive head-to-head studies [2].

Wider context: other reviews and registered trials

A third source, a review of drug therapy for obesity in children and adolescents, names mazdutide and the triple receptor agonist retatrutide as examples of multi-target drugs that adult obesity research may increasingly focus on [3]. The review also points out that GLP-1 receptor agonists still face limits, including widespread gastrointestinal side effects and open questions about long-term neurodevelopmental safety in adolescents [3]. It calls for pediatric clinical trials to test the safety and efficacy of weight-loss medications in younger people [3]. The review does not present pediatric data on mazdutide.

Two trial registry entries show where research is heading. These are registrations, not results:

  • A phase 4 trial is recruiting to study the effect of mazdutide on coronary plaque in people with coronary atherosclerosis and overweight or obesity (record last updated October 13, 2026) [4].
  • A phase 2 study of IBI362, a development code for mazdutide, in people with MASH is listed as active but no longer recruiting (record last updated October 20, 2026) [5].

What we still don’t know

  • Durability. The meta-analysis authors say longer-term trials are needed to confirm whether the HbA1c and weight differences hold up [1].
  • Head-to-head evidence beyond dulaglutide. It has not been established in definitive head-to-head studies whether glucagon/GLP-1 dual agonists outperform GLP-1-only drugs in general [2].
  • Rarer side effects. With only three trials, the pooled safety data are limited, and most safety outcomes were rated moderate certainty [1]. The non-significant rise in hypoglycemia is one signal that larger trials could clarify [1].
  • Glucagon-to-GLP-1 balance. How the balance of the two signals in a given compound affects glucose control is still being worked out [2].
  • Heart and liver outcomes. Registered trials are examining coronary plaque and MASH, but they have not reported results [4, 5].
  • Younger people. There is a stated need for pediatric trials of weight-loss medications, and no pediatric mazdutide data are presented in these sources [3].

References

  1. Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome (2026). doi:10.1186/s13098-026-02248-3
  2. The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction–Associated Steatohepatitis—A Narrative Review with a Translational Focus. Obesity Reviews (2026). doi:10.1111/obr.70228
  3. The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications. Journal of Diabetes & Metabolic Disorders (2026). doi:10.1007/s40200-026-02110-3
  4. Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity. ClinicalTrials.gov NCT07657676, status: recruiting.
  5. A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH). ClinicalTrials.gov NCT06937749, status: active not recruiting.

Image credits

Free to use (CC0 / public domain); credited as a courtesy.

  • Large Encapsulated Islets of Langerhans in Human Pancreas (47673151642).jpg, by Berkshire Community College Bioscience Image Library (CC0, via wikimedia-commons): source
  • Connective Tissue Adipose (41066512834).jpg, by Berkshire Community College Bioscience Image Library (CC0, via wikimedia-commons): source